TARA — Protara Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $138.11m
- -$32.18m
- 41
- 38
- 58
- 42
Annual cashflow statement for Protara Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -34 | -47.3 | -66 | -40.4 | -44.6 |
| Depreciation | |||||
| Non-Cash Items | 9.84 | 13.1 | 38.7 | 6.66 | 4.45 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.629 | -0.516 | 0.539 | -4.14 | 4.01 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -23.4 | -34.5 | -26.5 | -37.6 | -35.8 |
| Capital Expenditures | -0.884 | -0.596 | -0.12 | -0.045 | -0.063 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.72 | -97.6 | 15.1 | 53.2 | 19.2 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 2.83 | -98.2 | 14.9 | 53.1 | 19.2 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 189 | -0.228 | -0.09 | -0.091 | 140 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 169 | -133 | -11.6 | 15.5 | 123 |